Appendix 3 Research input, output and funding

Appendix 3 | Research input (personnel)

About the metrics

To collect the metrics of our research institute we followed the Strategy Evaluation Protocol of the Universities of the Netherlands (UNL, former VSNU), the Netherlands Organization for Scientific Research (NWO), and the Royal Netherlands Academy of Arts and Sciences (KNAW). As for funding categorization for the university medical centers, we used the Netherlands Federation of University Medical Centers (NFU) criteria. In the ratio-conversion from personnel to the full-time-equivalent (FTE) spent on research the default guidelines (HRM-SAP instructed) can be applied: full professor: 0.1-0.2 FTE; strategic professor: 0.1-0.2 FTE; associate professor: 0.2-0.4 FTE; assistant professor: 0.4; investigator: 0.6-0.8 FTE; postdoc: 0.85 FTE; PhD candidate: 0.75 FTE.

Amsterdam Neuroscience – Research institute (unique personnel counts)

The collective ‘community’ of the Amsterdam Neuroscience research institute over the years ranged from 784-1025 investigators. This included over 150 Principal Investigators, around 100 faculty members & residents, more than 200 postdocs and research associates, and between 376-479 PhD candidates per year.

Amsterdam Neuroscience – Research program affiliations

Shown here are also the research program affiliations of all personnel as well as the affiliations of PhD candidates only. Double affiliations were allowed, in particular for Principal Investigators.

Table 3.1 Personnel of the Amsterdam Neuroscience research institute over the years 2016-2021, divided per research program. The first table shows all personnel, followed by Phd candidates only.

All personnel Affiliations subtotals Year Total bi nt bm ctg nd nii ndis cia map 2016 863 89 48 201 50 137 119 40 100 96 2017 1025 114 62 261 80 182 149 64 128 114 2018 877 118 51 244 83 177 137 74 132 109 Year Total bi snn cmm ctg nd nii ndis cia mapss 2019 888 122 61 252 73 190 147 84 145 98 2020 877 111 58 225 73 179 142 76 120 90 2021 784 95 61 216 78 150 106 71 102 88

PhD candidates only Affiliations subtotals Year Total bi nt bm ctg nd nii ndis cia map 2016 416 43 23 97 24 66 57 19 48 46 2017 479 53 25 117 37 85 70 30 60 53 2018 439 40 18 108 32 82 67 32 54 39 Year Total bi snn cmm ctg nd nii ndis cia mapss 2019 453 58 20 145 33 81 86 50 84 44 2020 427 55 19 137 32 70 72 37 70 35 2021 376 47 23 128 31 60 52 36 54 35

* The column Total indicates the total number of affiliations to Amsterdam Neuroscience over the years. It is not equivalent to the sum of the research program affiliation subtotals, since double affiliations to research programs are also taken into account (for example, one Principal Investigator can be affiliated to two different research programs).

Appendix 3 | Research output

Table 3.2.1 Publications of the Amsterdam Neuroscience research institute in the period 2016-2018, divided per research program.

2016 Total bi nt bm ctg nd nii ndis cia map Refereed article 1242 123 52 221 91 194 149 123 105 184 Non-Refereed article (1) 15 2 1 2 2 3 0 0 2 3 Books 1 0 1 0 0 0 0 0 0 0 Book chapters 10 0 0 6 0 2 0 0 0 2 PhD theses 105 10 6 42 5 14 7 5 13 3 Conference papers 8 3 0 0 0 0 0 1 2 2 Professional publication (2) 35 1 4 4 0 13 2 2 2 7 Publications aimed at the general public (3) 5 0 0 1 0 0 2 0 1 1 Other research output (4) 13 0 0 1 0 0 2 1 4 5 Total publications 1434 139 64 277 98 226 162 132 129 207 With impact > 10 Subtotal bi nt bm ctg nd nii ndis cia map Refereed articles (selected output) 143 4 7 25 29 22 16 6 5 29 With impact > 5 < 10 Subtotal bi nt bm ctg nd nii ndis cia map Refereed articles (selected output) 313 27 16 53 21 60 35 33 14 54

2017 Total bi nt bm ctg nd nii ndis cia map Refereed article 1264 123 19 295 99 161 191 96 76 204 Non-Refereed article (1) 4 0 0 0 0 1 0 0 1 2 Books 2 0 0 0 0 2 0 0 0 0 Book chapters 15 3 0 2 1 1 0 3 0 5 PhD theses 60 11 1 17 2 5 5 5 9 5 Conference papers 3 3 0 0 0 0 0 0 0 0 Professional publication (2) 27 1 0 2 1 3 5 1 6 8 Publications aimed at the general public (3) 4 0 0 0 0 0 0 0 2 2 Other research output (4) 30 1 0 2 3 3 6 9 4 2 Total publications 1409 142 20 318 106 176 207 114 98 228 With impact > 10 Subtotal bi nt bm ctg nd nii ndis cia map Refereed articles (selected output) 130 2 3 27 26 17 16 10 9 20 With impact > 5 < 10 Subtotal bi nt bm ctg nd nii ndis cia map Refereed articles (selected output) 316 20 6 90 17 46 61 24 9 43

2018 Total bi nt bm ctg nd nii ndis cia map Refereed article 1239 121 46 235 67 191 158 99 95 227 Non-Refereed article (1) 25 2 2 0 2 4 4 6 4 1 Books 1 0 1 0 0 0 0 0 0 0 Book chapters 6 0 0 2 0 0 0 0 0 4 PhD theses 99 10 6 41 4 11 6 5 13 3 Conference papers 8 3 0 0 0 0 0 1 2 2 Professional publication (2) 24 1 0 2 0 2 3 3 8 5 Publications aimed at the general public (3) 1 0 0 1 0 0 0 0 0 0 Other research output (4) 4 0 0 1 0 0 2 1 0 0 Total publications 1407 137 55 282 73 208 173 115 122 242 With impact > 10 Subtotal bi nt bm ctg nd nii ndis cia map Refereed articles (selected output) 160 2 2 30 23 28 21 12 13 29 With impact > 5 < 10 Subtotal bi nt bm ctg nd nii ndis cia map Refereed articles (selected output) 284 19 4 64 10 65 49 33 10 30

Amsterdam Neuroscience – Research output

Shown here are the metrics for all types of publications. Double affiliations are not shown, i.e., each publication in this table is a unique product, only affiliated with one research program.

Table 3.2.2 Publications of the Amsterdam Neuroscience research institute in the period 2019-2021, divided per research program.

2019 Total bi snn cmm ctg nd nii ndis cia mapss Refereed article 1338 157 33 205 92 234 190 127 101 199 Non-Refereed article (1) 50 3 0 9 2 9 10 5 6 6 Books 0 0 0 0 0 0 0 0 0 0 Book chapters 23 4 0 10 3 2 0 1 1 2 PhD theses 83 8 7 9 4 15 18 6 6 10 Conference papers 13 7 0 0 0 3 0 1 2 0 Professional publication (2) 71 1 2 4 1 15 7 4 17 20 Publications aimed at the general public (3) 2 0 0 0 0 1 0 0 0 1 Other research output (4) 11 1 1 1 0 5 1 0 1 1 Total publications 1591 181 43 238 102 284 226 144 134 239 With impact > 10 Subtotal bi snn cmm ctg nd nii ndis cia mapss Refereed articles (selected output) 175 7 6 32 27 41 20 7 15 20 With impact > 5 < 10 Subtotal bi snn cmm ctg nd nii ndis cia mapss Refereed articles (selected output) 317 27 10 61 24 53 62 25 21 34

2020 Total bi snn cmm ctg nd nii ndis cia mapss Refereed article 1315 125 31 207 86 238 184 119 95 230 Non-Refereed article (1) 61 5 2 10 6 9 5 7 7 10 Books 0 0 0 0 0 0 0 0 0 0 Book chapters 15 1 2 1 0 3 2 2 2 2 PhD theses 86 8 4 14 7 14 19 8 4 8 Conference papers 9 7 0 0 0 1 0 1 0 0 Professional publication (2) 64 3 1 5 2 10 3 5 15 20 Publications aimed at the general public (3) 0 0 0 0 0 0 0 0 0 0 Other research output (4) 24 6 0 2 0 3 1 1 3 8 Total publications 1574 155 40 239 101 278 214 143 126 278 With impact > 10 Subtotal bi snn cmm ctg nd nii ndis cia mapss Refereed articles (selected output) 175 7 2 33 34 32 15 14 10 28 With impact > 5 < 10) Subtotal bi snn cmm ctg nd nii ndis cia mapss Refereed articles (selected output) 354 33 4 61 14 63 72 38 11 58

2021 Total bi snn cmm ctg nd nii ndis cia mapss Refereed article 1597 187 41 203 105 258 229 176 132 266 Non-Refereed article (1) 74 7 2 11 9 15 13 7 6 4 Books 2 0 0 0 0 0 0 0 1 1 Book chapters 17 4 0 9 0 1 0 1 1 1 PhD theses 90 5 1 23 1 16 9 12 6 17 Conference papers 26 25 1 0 0 0 0 0 0 0 Professional publication (2) 40 0 0 3 1 5 3 2 10 16 Publications aimed at the general public (3) 3 0 1 0 0 0 0 1 0 1 Other research output (4) 48 9 11 3 3 2 8 3 3 6 Total publications 1897 237 57 252 119 297 262 202 159 312 With impact > 10 Subtotal bi snn cmm ctg nd nii ndis cia mapss Refereed articles (selected output) 276 16 17 34 32 70 41 20 12 34 With impact > 5 < 10) Subtotal bi snn cmm ctg nd nii ndis cia mapss Refereed articles (selected output) 256 42 4 42 17 39 47 10 13 42

Notes on the distinct categories (according to the latest SEP protocol):

1. Articles in journals that are non-refereed, yet deemed important for the field; 2. Publications aimed at professionals in the public and private sector (professional publications), including patents and annotations (e.g., law); 3. Also known as ‘populariserende artikelen’; 4. Other types of research output (if applicable), such as abstracts, patents, editorships, inaugural lectures, designs and prototypes (e.g., engineering) and media appearances.

TOP 5 Publications

Brain Imaging

• van den Heuvel MP, Sporns O. A cross-disorder connectome landscape of brain dysconnectivity. Nat Rev Neurosci. 2019

Jul;20(7):435-446. • de Ruiter MB, Reneman L, Kieffer JM, Oldenburg HSA, Schagen SB.

Brain White Matter Microstructure as a Risk Factor for Cognitive

Decline After Chemotherapy for Breast Cancer. J Clin Oncol. 2021

Dec 10;39(35):3908-3917. • Schrantee A, Tamminga HG, Bouziane C, Bottelier MA, Bron

EE, Mutsaerts HJ, Zwinderman AH, Groote IR, Rombouts SA,

Lindauer RJ, Klein S, Niessen WJ, Opmeer BC, Boer F, Lucassen

PJ, Andersen SL, Geurts HM, Reneman L. Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder: A

Randomized Clinical Trial. JAMA Psychiatry. 2016 Sep 1;73(9):955-62. • Chard DT, Alahmadi AAS, Audoin B, Charalambous T, Enzinger C,

Hulst HE, Rocca MA, Rovira À, Sastre-Garriga J, Schoonheim MM,

Tijms B, Tur C, Gandini Wheeler- Kingshott CAM, Wink AM, Ciccarelli

O, Barkhof F; MAGNIMS Study Group. Mind the gap: from neurons to networks to outcomes in multiple sclerosis. Nat Rev Neurol. 2021

Mar;17(3):173-184. • Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N,

Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL,

Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof

F; MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016

Mar;15(3):292-303.

Systems & Network Neuroscience

• Chen X, Wang F, Fernandez E, Roelfsema PR. Shape perception via a high-channel-count neuroprosthesis in monkey visual cortex.

Science. 2020 Dec 4;370(6521):1191-1196. doi: 10.1126/science. abd7435. • Dore K, Carrico Z, Alfonso S, Marino M, Koymans K, Kessels

HW, Malinow R. PSD-95 protects synapses from beta-amyloid.

Cell Reports 2021. 2021 Jun 1; 35 (9): doi: 10.1016/j. celrep.2021.109194. • de Kloet SF, Bruinsma B, Terra H, Heistek TS, Passchier EMJ, van den

Berg AR, Luchicchi A, Min R, Pattij T, Mansvelder HD. Bi-directional regulation of cognitive control by distinct prefrontal cortical output neurons to thalamus and striatum. Nature Commun. 2021 Mar 31;12(1):1994. doi: 10.1038/s41467-021-22260-7. • Blanken TF, Benjamins JS, Borsboom D, Vermunt JK, Paquola C,

Ramautar J, Dekker K, Stoffers D, Wassing R, Wei Y, van Someren

EJW. Insomnia disorder subtypes derived from life history and traits of affect and personality. The Lancet Psychiatry 2019 6(2): 151-163. • Zimmer TS, David B, Broekaart DWM, Schidlowski M, Ruffolo G,

Korotkov A, van der Wel NN, van Rijen PC, Mühlebner A, van Hecke

W, Baayen JC, Idema S, François L, van Eyll J, Dedeurwaerdere S,

Kessels HW, Surges R, Rüber T, Gorter JA, Mills JD, van Vliet EA,

Aronica E. Seizure-mediated iron accumulation and dysregulated iron metabolism after status epilepticus and in temporal lobe epilepsy. Acta Neuropathol. 2021 142 (4), 729-759.

Cellular & Molecular Mechanisms

• Koopmans F, van Nierop P, Andres-Alonso M, Byrnes A, Cijsouw

T, Coba MP, Cornelisse LN, Farrell RJ, Goldschmidt HL, Howrigan

DP, Hussain NK, Imig C, de Jong APH, Jung H, Kohansalnodehi M,

Kramarz B, Lipstein N, Lovering RC, MacGillavry H, Mariano V, Mi H,

Ninov M, Osumi-Sutherland D, Pielot R, Smalla KH, Tang H, Tashman

K, Toonen RFG, Verpelli C, Reig-Viader R, Watanabe K, van Weering

J, Achsel T, Ashrafi G, Asi N, Brown TC, De Camilli P, Feuermann

M, Foulger RE, Gaudet P, Joglekar A, Kanellopoulos A, Malenka R,

Nicoll RA, Pulido C, de Juan-Sanz J, Sheng M, Südhof TC, Tilgner

HU, Bagni C, Bayés À, Biederer T, Brose N, Chua JJE, Dieterich DC,

Gundelfinger ED, Hoogenraad C, Huganir RL, Jahn R, Kaeser PS, Kim

E, Kreutz MR, McPherson PS, Neale BM, O’Connor V, Posthuma D,

Ryan TA, Sala C, Feng G, Hyman SE, Thomas PD, Smit AB, Verhage M.

SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the

Synapse. Neuron. 2019 Jul 17;103(2):217-234.e4. doi: 10.1016/j. neuron.2019.05.002. Epub 2019 Jun 3. • Persoon CM, Hoogstraaten RI, Nassal JP, van Weering JRT,

Kaeser PS, Toonen RF, Verhage M. The RAB3-RIM Pathway Is

Essential for the Release of Neuromodulators. Neuron. 2019 Dec 18;104(6):1065-1080.e12. doi:10.1016/j.neuron.2019.09.015. Epub 2019 Oct 31. • Rosato M, Stringer S, Gebuis T, Paliukhovich I, Li KW, Posthuma

D, Sullivan PF, Smit AB, van Kesteren RE. Combined cellomics and proteomics analysis reveals shared neuronal morphology and molecular pathway phenotypes for multiple schizophrenia risk genes. Mol Psychiatry. 2021 Mar;26(3):784-799. doi:10.1038/s41380019-0436-y. Epub 2019 May 29. • Wang XL, Kooijman S, Gao Y, Tzeplaeff L, Cosquer B, Milanova I,

Wolff SEC, Korpel N, Champy MF, Petit-Demoulière B, Goncalves Da

Cruz I, Sorg-Guss T, Rensen PCN, Cassel JC, Kalsbeek A, Boutillier AL,

Yi CX. Microglia-specific knock-down of Bmal1 improves memory and protects mice from high fat diet-induced obesity. Mol Psychiatry. 2021 Nov;26(11):6336-6349. • Zimmer TS, David B, Broekaart DWM, Schidlowski M, Ruffolo G,

Korotkov A, van der Wel NN, van Rijen PC, Mühlebner A, van Hecke

W, Baayen JC, Idema S, François L, van Eyll J, Dedeurwaerdere S,

Kessels HW, Surges R, Rüber T, Gorter JA, Mills JD, van Vliet EA,

Aronica E. Seizure-mediated iron accumulation and dysregulated iron metabolism after status epilepticus and in temporal lobe epilepsy. Acta Neuropathol. 2021 Oct;142(4):729-759.

Complex Trait Genetics

• Ian Fiddes, Gerrald Lodewijk, Meghan Mooring, Colleen M.

Bosworth, Adam Ewing, Gary Mantalas, Adam Novak, Anouk van den

Bout, Alex Bishara, Jimi L. Rosenkrantz, Ryan Lorig-Roach, Andrew

R. Field, Maximilian Haeussler, Lotte Russo, Aparna Bhaduri, Tomasz

Nowakowski, Alex Pollen, Max Dougherty, Xander Nuttle, Marie

Claude Addor, Simon Zwolinski, Sol Katzman, Arnold Kriegstein, Evan

E. Eichler, Sofie R. Salama, Frank M.J. Jacobs #, David Haussler #. Human-specific NOTCH2NL genes affect Notch signaling and cortical neurogenesis. Cell, 173(6):1356-1369. (2018) (#Shared Last/ corresponding authors). • Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland

D, Rongve A, Børte S, Winsvold BS, Drange OK, Martinsen AE,

Skogholt AH, Willer C, Bråthen G, Bosnes I, Nielsen JB, Fritsche LG,

Thomas LF, Pedersen LM, Gabrielsen ME, Johnsen MB, Meisingset

TW, Zhou W, Proitsi P, Hodges A, Dobson R, Velayudhan L; 23andMe

Research Team, Sealock JM, Davis LK, Pedersen NL, Reynolds CA,

Karlsson IK, Magnusson S, Stefansson H, Thordardottir S, Jonsson

PV, Snaedal J, Zettergren A, Skoog I, Kern S, Waern M, Zetterberg

H, Blennow K, Stordal E, Hveem K, Zwart JA, Athanasiu L, Selnes

P, Saltvedt I, Sando SB, Ulstein I, Djurovic S, Fladby T, Aarsland

D, Selbæk G, Ripke S, Stefansson K, Andreassen OA, Posthuma

D. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat Genet. 2021

Sep;53(9):1276-1282.

• Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg

S, Sealock J, Karlsson IK, Hägg S, Athanasiu L, Voyle N, Proitsi P,

Witoelar A, Stringer S, Aarsland D, Almdahl IS, Fred Andersen F,

Bergh S, Bettella F, Bjornsson S, Brækhus A, Bråthen G, de Leeuw

CA, Desikan RS, Djurovic S, Dumitrescu L, Fladby T, Homan T,

Jonsson PV, Kiddle SJ, Rongve KA, Saltvedt I, Sando SB, Selbæk G,

Shoai M, Skene N, Snaedal J, Stordal E, Ulstein ID, Wang Y, White

LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson

R, Davis LK, Stefansson H, Stefansson K, Pedersen NL, Stephan Ripke

S, Andreassen OA, Posthuma D. Genetic meta-analysis identifies 9 novel loci and functional pathways for Alzheimer’s disease risk.

Nature Genetics. 2019 Mar;51(3):404-413. • Jansen PR, Watanabe K, Stringer S, Skene N, Bryois J,

Hammerschlag AR, de Leeuw CA, Benjamins J, Muñoz-Manchado AB,

Nagel M, Savage JE, Tiemeier H, White T, The 23andMe Research

Team, JY, Hinds DA. Vacic V, Sullivan PF, van der Sluis S, Polderman

TJ, Smit AB, Hjerling-Leffler J, Van Someren EJW, Posthuma D.

Genome-wide Study of Insomnia (N=1,331,010) Identifies Novel

Genetic Loci and Functional Pathways. Nature Genetics. 2019

Mar;51(3):394-4032019. • Werme J, van der Sluis S, Posthuma D, de Leeuw CA. An integrated framework for local genetic correlation analysis. Nat Genet. 2022

Mar;54(3):274-282. doi: 10.1038/s41588-022-01017-y. Epub 2022 Mar 14. PMID: 35288712.

Neurodegeneration

• van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens

P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters

O, Rüther E, Nobili F, Frisoni GB, Spiru L, Freund-Levi Y, Wallin

AK, Hampel H, Soininen H, Tsolaki M, Verhey F, Kłoszewska I,

Mecocci P, Vellas B, Lovestone S, Galluzzi S, Herukka SK, Santana I,

Baldeiras I, de Mendonça A, Silva D, Chetelat G, Egret S, Palmqvist

S, Hansson O, Visser PJ, Berkhof J, van der Flier WM; Alzheimer’s

Disease Neuroimaging Initiative. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol. 2019 Nov;18(11):1034-1044. doi: 10.1016/

S1474-4422(19)30283-2. • Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat

G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer’s disease. Lancet. 2021 Apr 24;397(10284):1577-1590. doi: 10.1016/

S0140-6736(20)32205-4. • Holewijn RA, Verbaan D, van den Munckhof PM, Bot M, Geurtsen

GJ, Dijk JM, Odekerken VJ, Beudel M, de Bie RMA, Schuurman PR.

General Anesthesia vs Local Anesthesia in Microelectrode Recording-

Guided Deep-Brain Stimulation for Parkinson Disease: The GALAXY

Randomized Clinical Trial. JAMA Neurol 2021;78(10):1212-1219. • Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro

PP, Castaño-Díez D, Schweighauser G, Graff-Meyer A, Goldie KN,

Sütterlin R, Huisman E, Ingrassia A, Gier Y, Rozemuller AJM, Wang J,

Paepe A, Erny J, Staempfli A, Hoernschemeyer J, Großerüschkamp

F, Niedieker D, El-Mashtoly SF, Quadri M, Van IJcken WFJ, Bonifati V,

Gerwert K, Bohrmann B, Frank S, Britschgi M, Stahlberg H, Van de

Berg WDJ, Lauer ME. Nat Neurosci. 2019 Jul;22(7):1099-1109. • Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten

JJ, van Laar T, Tissingh G, Munts AG, Deuschl G, Lang AE, Dijkgraaf

MGW, de Haan RJ, de Bie RMA; LEAP Study Group. Randomized

Delayed-Start Trial of Levodopa in Parkinson’s Disease. N Eng J Med, 2019.

Neuroinfection & -Inflammation

• van de Beek D, Brouwer MC, Koedel U, Wall EC. Communityacquired bacterial meningitis. Lancet. 2021;398:1171-1183. • Lees JA, (…) Brouwer MC, Barrett JC, Bentley SD, van de Beek

D. Joint sequencing of human and pathogen genomes reveals the genetics of pneumococcal meningitis. Nat Commun. 2019;10:217. • Adrichem, ME, Lucke IM (…) de Haan RIJ, van Schaik IN, Eftimov F.

Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 2022 Epub. • Wattjes MP, Ciccarelli O, Reich DS, (…), Rovira À; Magnetic

Resonance Imaging in Multiple Sclerosis study group; Consortium of Multiple Sclerosis Centres; North American Imaging in Multiple

Sclerosis Cooperative MRI guidelines working group. 2021 MAGNIMS-

CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20:653-670. • van Olst L, Rodriguez-Mogeda C, (…) de Vries HE, Reynolds R, Witte

ME. Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration. Acta Neuropathol 2021;141:881-899.

Neurovascular Disorders

• Van den Berg, et al. Two-Year Outcome after Endovascular

Treatment for Acute Ischemic Stroke. N Engl J Med, 2017. • LeCouffe, et al. A Randomized Trial of Intravenous Alteplase before

Endovascular Treatment for Stroke. N Engl J Med, 2021. • Post et al. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. Lancet 2021. • Sanchez van Kammen et al. Frequency of Thrombocytopenia and

Platelet Factor 4/Heparin Antibodies in Patients With Cerebral

Venous Sinus Thrombosis Prior to the COVID-19 Pandemic. JAMA 2021. • Coutinho et al. Effect of Endovascular Treatment With Medical

Management vs Standard Care on Severe Cerebral Venous

Thrombosis: The TO-ACT Trial. JAMA Neurology 2020.

Compulsivity, Impulsivity & Attention

• Shephard, E, Stern, ER, van den Heuvel, OA, Costa, DLC, Batistuzzo,

MC, Godoy, PBG, Lopes, AC, Brunoni, AR, Hoexter, MQ, Shavitt,

RG, Reddy, YCJ, Lochner, C, Stein, DJ, Simpson, HB & Miguel, EC 2021, ‘Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder’, Molecular Psychiatry, vol. 26, no. 9, pp. 4583-4604. • Vezoli, J, Vinck, M, Bosman, CA, Bastos, AM, Lewis, CM, Kennedy, H & Fries, P 2021, ‘Brain rhythms define distinct interaction networks with differential dependence on anatomy’, Neuron, vol. 109, no. 23, pp. 3862-3878.e5. • Graat, I, Mocking, R, Figee, M, Vulink, N, de Koning, P, Ooms, P,

Mantione, M, van den Munckhof, P, Schuurman, R & Denys, D 2021,

‘Long-term Outcome of Deep Brain Stimulation of the Ventral

Part of the Anterior Limb of the Internal Capsule in a Cohort of 50

Patients With Treatment-Refractory Obsessive-Compulsive Disorder’,

Biological psychiatry, vol. 90, no. 10, pp. 714-720. • Mistarz, N, Andersen, K, Nielsen, ASG, Goudriaan, AE, Michel,

TM, Skøt, L, Nielsen, DG & Mellentin, AI 2021, ‘Pharmacological enhancing agents targeting cognition in patients with alcoholinduced neurocognitive disorders: A systematic review’,

Neuroscience and biobehavioral reviews, vol. 125, pp. 608-626. • Weeland, CJ, White, T, Vriend, C, Muetzel, RL, Starreveld, J,

Hillegers, MHJ, Tiemeier, H & van den Heuvel, OA 2021, ‘Brain

Morphology Associated With Obsessive-Compulsive Symptoms in 2,551 Children From the General Population’, Journal of the

American Academy of Child and Adolescent Psychiatry, vol. 60, no. 4, pp. 470-478.

Mood, Anxiety, Psychosis, Stress & Sleep

• Jansen, R., Han, Laura KM, Verhoeven, Josine E, Aberg, Karolina A, van den Oord, Edwin CGJ, Milaneschi, Yuri, Penninx, Brenda WJH.

An integrative study of five biological clocks in somatic and mental health. eLife 2021;10:e59479 DOI: 10.7554/eLife.59479. • Milaneschi Y, Lamers F, Berk M, Penninx BWJH. Depression

Heterogeneity and Its Biological Underpinnings: Toward

Immunometabolic Depression. Biol Psychiatry. 2020 Sep 1;88(5):369-380. doi: 10.1016/j.biopsych.2020.01.014. Epub 2020

Jan 28. PMID: 32247527. • Spijker S, Koskinen MK, Riga D. Incubation of depression:

ECM assembly and parvalbumin interneurons after stress.

Neurosci Biobehav Rev. 2020 Nov;118:65-79. doi: 10.1016/j. neubiorev.2020.07.015. • Rao-Ruiz P, Couey JJ, Marcelo IM, Bouwkamp CG, Slump

DE, Matos MR, van der Loo RJ, Martins GJ, van den Hout M, van IJcken WF, Costa RM, van den Oever MC, Kushner SA.

Engram-specific transcriptome profiling of contextual memory consolidation. Nat Commun. 2019 May 20;10(1):2232. doi: 10.1038/ s41467-019-09960-x. • Matos MR, Visser E, Kramvis I, van der Loo RJ, Gebuis T, Zalm R,

Rao-Ruiz P, Mansvelder HD, Smit AB, van den Oever MC. Memory strength gates the involvement of a CREB-dependent cortical fear engram in remote memory. Nat Commun. 2019 May 24;10(1):2315. doi: 10.1038/s41467-019-10266-1.

Appendix 3 | Funding

Amsterdam Neuroscience – Research funding

Shown here is the grand total and the subtotals per type of funding and per research program of newly acquired funding for the institute. In this table funding that is unique to each particular research program is shown.

Table 3.3 Funding acquired in the period 2016-2021, divided per research program.

2016 Grand total bi nt bm ctg nd nii ndis cia map Total € 41,978,650 1,877,855€ 1,023,783€ 10,039,266€ 2,854,634€ 9,117,952€ 4,537,160€ 1,233,638€ 4,571,232€ 6,773,131€ Subtotal Total bi nt bm ctg nd nii ndis cia map 1st cash flow 1,450,000 € 100,000€ 50,000€ 530,000€ 320,000€ 200,000€ 100,000€ 50,000€ 50,000€ 50,000€ 2nd cash flow 26,347,126 € 545,167€ 546,875€ 8,237,389€ 2,330,946€ 2,432,321€ 1,665,719€ 1,183,638€ 4,421,232€ 4,983,839€ 3rd cash flow 4,041,767 € 350,000€ € 511,000 € 203,688€ 1,766,079€ 1,161,000€ -€ € 50,000 € 4th cash flow 10,139,757 € 882,688€ 426,908€ 760,877€ € 4,719,552 € 1,560,441€ € 100,000 € 1,689,292€

2017 Grand total bi nt bm ctg nd nii ndis cia map Total € 49,405,912 2,221,590€ 2,267,967€ 13,910,948€ 3,002,456€ 11,926,221€ 5,564,970€ 5,240,768€ 1,621,742€ 3,649,251€ Subtotal Total bi nt bm ctg nd nii ndis cia map 1st cash flow 3,546,691 € 520,493€ 249,081€ 545,556€ 55,556€ 73,325€ 737,684€ 940,520€ 132,742€ 291,738€ 2nd cash flow 27,725,790 € 1,534,227€ 2,000,140€ 6,411,959€ 2,433,400€ 6,118,984€ 1,797,643€ 2,947,309€ 1,489,000€ 2,993,127€ 3rd cash flow 10,514,423 € -€ € 3,475,306 € 513,500€ 3,877,056€ 1,161,511€ 1,337,939€ € 149,111 € 4th cash flow 7,619,008 € 166,870€ 18,746€ 3,478,128€ € 1,856,855 € 1,868,132€ 15,000€ € 215,276 €

2018 Grand total bi nt bm ctg nd nii ndis cia map Total € 46,898,432 4,362,519€ 2,789,366€ 9,843,349€ 1,779,000€ 14,404,356€ 3,570,396€ 3,411,563€ 2,746,192€ 3,991,691€ Subtotal Total bi nt bm ctg nd nii ndis cia map 1st cash flow 2,080,235 € 558,729€ 50,000€ 606,444€ -€ € 144,618 € 649,444€ € 71,000 € 2nd cash flow 23,627,387 € 2,918,855€ 2,489,366€ 4,403,671€ 909,000€ 6,415,353€ 497,536€ 636,242€ 1,596,619€ 3,760,745€ 3rd cash flow 11,118,757 € 88,347€ 250,000€ 3,635,224€ 870,000€ 2,058,902€ 914,082€ 1,992,682€ 1,149,573€ 159,946€ 4th cash flow 10,072,053 € 796,588€ € 1,198,010 € € 5,930,100 € 2,014,160€ 133,195€ -€ -€

Table 3.3 continues on the next page

NFU definition

• 1st cash flow: Shown is internal so-called alliance funding (i.e., 2,475 k€) only; the unconditional internal funding for tenured and other personnel is estimated to be > 50 M€ per year in the period 2016-2021; • 2nd cash flow: conditional funding by intermediary public bodies and agencies (ZonMw, NWO, KNAW and the EU); • 3rd cash flow: private funding by non-profit organizations; • 4th cash flow: private funding from commercial sources: contract-research and clinical trial research funded by biotech and pharma industry and acquired by the Industry Alliance Office (IAO).

2019 Grand total bi snn cmm ctg nd nii ndis cia mapss Total € 76,429,394 9,152,036€ 5,122,629€ 10,134,647€ 6,908,639€ 16,026,305€ 16,822,569€ 2,833,940€ 4,130,124€ 5,298,505€ Subtotal Total bi snn cmm ctg nd nii ndis cia mapss 1st cash flow 2,475,000 € 275,000€ 275,000€ 275,000€ 275,000€ 275,000€ 275,000€ 275,000€ 275,000€ 275,000€ 2nd cash flow 33,050,876 € 1,954,261€ 4,552,594€ 6,104,601€ 6,047,038€ 2,615,253€ 4,952,669€ 1,116,100€ 3,255,691€ 2,452,669€ 3rd cash flow 20,617,131 € 607,957€ 235,598€ 1,813,915€ 355,159€ 8,946,905€ 5,778,114€ 521,858€ 584,133€ 1,773,493€ 4th cash flow 20,286,387 € 6,314,818€ 59,436€ 1,941,132€ 231,442€ 4,189,147€ 5,816,787€ 920,982€ 15,300€ 797,344€

2020 Grand total bi snn cmm ctg nd nii ndis cia mapss Total € 55,337,353 4,609,550€ 1,614,398€ 5,894,371€ 3,842,748€ 18,151,277€ 8,811,804€ 3,118,457€ 1,855,320€ 7,439,428€ Subtotal Total bi snn cmm ctg nd nii ndis cia mapss 1st cash flow - -€ -€ -€ -€ -€ -€ -€ -€ -€ 2nd cash flow 18,449,232 € 343,072€ 446,652€ 1,695,704€ 1,287,843€ 6,431,234€ 2,606,456€ 259,000€ 636,706€ 4,742,565€ 3rd cash flow 23,774,947 € 3,687,765€ 854,828€ 3,679,355€ 2,213,021€ 5,020,705€ 3,377,525€ 1,620,607€ 624,278€ 2,696,863€ 4th cash flow 13,113,174 € 578,713€ 312,918€ 519,312€ 341,884€ 6,699,338€ 2,827,823€ 1,238,850€ 594,336€ -€

2021 Grand total bi snn cmm ctg nd nii ndis cia mapss Total € 75,838,309 3,168,770€ 7,581,991€ 11,789,080€ 2,566,374€ 22,442,323€ 9,827,684€ 1,595,841€ 13,127,942€ 3,738,304€ Subtotal Total bi snn cmm ctg nd nii ndis cia mapss 1st cash flow 415,921 € -€ € 365,921 € -€ € 25,000 € -€ € 25,000 € 2nd cash flow 32,088,842 € 1,237,715€ 855,000€ 3,745,032€ 1,939,192€ 5,636,753€ 5,964,102€ 406,491€ 8,676,153€ 3,628,404€ 3rd cash flow 29,435,643 € 746,305€ 6,691,397€ 2,844,817€ 528,072€ 10,828,814€ 3,087,634€ 1,164,000€ 3,530,704€ 13,900€ 4th cash flow 13,897,903 € 1,184,750€ 35,594€ 4,833,310€ 99,110€ 5,976,756€ 750,948€ 25,350€ 921,085€ 71,000€